The OBSERVE Protocol is a long-term study that looks at how patients do over time with two treatments: Spravato® and IV ketamine. These treatments are for treatment-resistant depression (TRD), which means depression that hasn't improved after trying two or more medicines. This study aims to understand how patients feel about these treatments, how they use them, and if they are safe and effective in the long run.
The study will last for 5 years and take place at 6 different locations, including both hospitals and community practices. It seeks to enroll 450 patients who are either starting or continuing treatment with Spravato® or IV ketamine.
- Study involves regular check-ins over 5 years.
- Participants must be 18 or older and agree to the study terms.
- People with bipolar disorder or substance use disorder cannot join.
Participants must be willing to participate for the entire study duration. This study helps gather important information to improve future treatments for depression.